Use of eVLP-based vaccine candidates to broaden immunity against SARS-CoV-2 variants bioRxiv September 2021
An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits potent immunity after a single dose Vaccine July 2021

Robust Immunogenicity and Rapid Onset of High Rates of Seroprotection and Anti-HBs Titers, Elicited with 3-Antigen Hepatitis B Vaccine in Adults Conference: 2021 International Symposium on Viral Hepatitis and Liver…

Evaluation of GM-CSF and AS01B Adjuvants in a Phase I/IIa Trial of a Therapeutic CMV Vaccine (VBI-1901) Against Recurrent Glioblastoma (GBM) Conference: 2021 American Society of Clinical Oncology (ASCO) Annual…
Assessment of immunogenicity and safety across two manufacturing lots of a 3-antigen hepatitis B vaccine, Sci-B-Vac®, compared with Engerix-B® in healthy Asian adults: a Phase 3 randomized clinical trial Vaccine…

Higher seroprotection rates (SPR) and higher anti-HBs concentrations in adults age 18-45 immunized with 3-antigen hepatitis B vaccine (3A-HBV) compared to 1-antigen hepatitis B vaccine (1A-HBV): Results from the pivotal,…
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a raondomised, double-blind phase 3 trial The Lancet Infectious Diseases May 2021
Rapid and high seroprotection rates achieved with a tri-antigenic hepatitis B vaccine in healthy young adults: Results from a Phase IV Study Vaccine February 2021